Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (NCT07828327) titled 'Real-World Effectiveness of Depemokimab in Allergic Bronchopulmonary Aspergillosis With Severe Eosinophilic Asthma' on Sept. 14.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Qianfoshan Hospital
Condition:
Allergic Bronchopulmonary Aspergillosis
ABPA
Severe Eosinophilic Asthma
Intervention:
Drug: Depemokimab
Recruitment Status: Not recruiting
Phase: N/A
Date of First Enrollment: November 1, 2026
Target Sample Size: 10
Countries of Recruitment:
China
To know more, visit htt...